Patents Examined by Brian J. Davis
  • Patent number: 11903937
    Abstract: Described herein are methods of treating metastatic castration-sensitive prostate cancer with anti-androgens, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.
    Type: Grant
    Filed: February 13, 2023
    Date of Patent: February 20, 2024
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Margaret K. Yu
  • Patent number: 11905270
    Abstract: The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a diseaseas a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: February 20, 2024
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Stefan Baeurle, Adam James Davenport, Christopher Stimson, Jens Nagel, Nicole Schmidt, Andrea Rotgeri, Ina Groeticke, Alexandra Rausch, Juergen Klar, Thomas Dyrks
  • Patent number: 11896558
    Abstract: The present specification provides improved methods of treating Her2+ cancers in which an RXR agonist and a taxane are administered to a subject having a Her2+ cancer. Thyroid hormone and other anticancer agents may also be administered. Related compositions and combination are also disclosed.
    Type: Grant
    Filed: December 7, 2022
    Date of Patent: February 13, 2024
    Assignees: Io Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Martin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar
  • Patent number: 11890288
    Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.
    Type: Grant
    Filed: July 20, 2023
    Date of Patent: February 6, 2024
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kiyomi Ohba, Yasuki Niwa, Tetsuji Matsudaira, Maiko Hamada, Ryuta Yamazaki, Tatsuya Ibuki
  • Patent number: 11890292
    Abstract: Provided herein are compositions, methods, systems and/or kits for preventing and/or treating neoplasms using at least one modulator selected from quercetin, sodium phenyl butyrate and epigallocatechin-3-gallate in combination with one or more anti-cancer agents. The compositions, methods, systems and/or kits are used to prevent and/or treat neoplasms that are resistant to the one or more anti-cancer agents when administered alone.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: February 6, 2024
    Assignee: Research Cancer Institute of America
    Inventor: Mohammed Amin Nezami
  • Patent number: 11878955
    Abstract: A compound 3,3?,3?-nitrilotris(1-(naphthalen-2-yloxy)propan-2-ol, its synthesis, and its use as an insecticidal agent.
    Type: Grant
    Filed: August 29, 2023
    Date of Patent: January 23, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Mohamed A. Gad
  • Patent number: 11878964
    Abstract: The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition. The invention also provides kits comprising urolithin and protein.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: January 23, 2024
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher L. Rinsch, William Blanco-Bose
  • Patent number: 11878018
    Abstract: The present invention relates to discovery that TBK1 phosphorylates Syntaxin 17 and that phosphorylation of Syntaxin 17 is intimate to control autophagy initiation. The present invention is directed to this discovery and the use of TBK1 inhibitors or inhibitors of Syntaxin 17 phosphorylation alone or in combination with additional bioactive agents to inhibit autophagy in the treatment of disease, especially the treatment of cancers. Methods of treating various cancers are disclosed using TBK1 inhibitors to patients with cancer and into cancerous tissues for the treatment of cancer including the inhibition, amelioration, reduction in metastasis and in recurrence of cancer in remission. Assays and methods for identifying compounds as inhibitors of Syntaxin 17 and as potential therapeutic agents for cancer and autoimmune diseases are also diseased herein.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: January 23, 2024
    Assignee: UNM RAINFOREST INNOVATIONS
    Inventors: Vojo P. Deretic, Suresh Kumar
  • Patent number: 11872203
    Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
    Type: Grant
    Filed: May 24, 2023
    Date of Patent: January 16, 2024
    Assignee: Axsome Malta Ltd.
    Inventor: Herriot Tabuteau
  • Patent number: 11872211
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: January 16, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Patent number: 11872204
    Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
    Type: Grant
    Filed: May 24, 2023
    Date of Patent: January 16, 2024
    Assignee: Axsome Malta Ltd.
    Inventor: Herriot Tabuteau
  • Patent number: 11873306
    Abstract: A novel nano-sized 5,10,15,20-Tetrakis (4-hydroxyphenyl)-Porphyrins Pd(II) complex, its synthesis, and its use for potential super medicinal applications.
    Type: Grant
    Filed: July 20, 2023
    Date of Patent: January 16, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Ahmed Mohammed Abu-Dief Mohammed, Ateyatallah Aljuhani, Salah Mohamed El Sayed
  • Patent number: 11858909
    Abstract: Disclosed herein are compounds, such as compounds of Formulae (I), (II), and (III), and d3-etoricoxib, and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, metabolites, and prodrugs thereof, and compositions, methods, uses, and kits thereof. The compounds disclosed herein are COX inhibitors and are therefore useful for the treatment and/or prevention of various conditions (e.g., inflammation, pain, or fever).
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: January 2, 2024
    Assignee: Tremeau Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Patent number: 11850239
    Abstract: Provided herein is a method of treating, preventing, or alleviating one or more symptoms of a disorder, disease, or condition mediated by an MDM2 with an MDM2 inhibitor, e.g., a compound of Formula (I), and a platinum compound. Also provided herein is a method of inhibiting the growth of a cell with an MDM2 inhibitor and a platinum compound.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: December 26, 2023
    Assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp Limited
    Inventors: Yifan Zhai, Dajun Yang
  • Patent number: 11851389
    Abstract: The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: December 26, 2023
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Dan Peer, Srinivas Ramishetti
  • Patent number: 11850259
    Abstract: This disclosure relates to topical lithium agents including inhalable lithium agents for treating a viral infection characterized by a cytokine storm in the respiratory tract of a subject such as a human. Topical lithium formulations can be used to mitigate such viral infections, including coronavirus infections.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: December 26, 2023
    Assignee: THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventor: Carl Ganio
  • Patent number: 11844800
    Abstract: Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof; or any combination thereof.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: December 19, 2023
    Assignees: Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.
    Inventors: Alexander K. Shalek, Peter Winter, David Weinstock, Mark Murakami, Scott Manalis, Andrew Navia, Jennyfer Galvez-Reyes
  • Patent number: 11834440
    Abstract: The disclosure provides for compounds and methods for modulating or inhibiting glutaminyl-peptide cyclotransferase-like protein (QPCTL). In one aspect, described herein are compounds of Formulas (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), and (IIbb), stereoisomer thereof, or salts or solvates thereof. Further provided herein are methods of treating a disease or a condition comprising administering a compound of Formula (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), or (IIbb), a stereoisomer thereof, or a salt or solvate thereof.
    Type: Grant
    Filed: February 16, 2023
    Date of Patent: December 5, 2023
    Assignee: Insilico Medicine IP Limited
    Inventors: Xin Cheng, Yingtao Liu, Luoheng Qin
  • Patent number: 11833128
    Abstract: The present disclosure provides a ketone carbonyl-containing hydrophobic antitumor drug and a conjugate thereof as well as a nano preparation containing the conjugate, a preparation method therefor, and an application thereof. The conjugate is an amphipathic pH-responsive conjugate obtained by enabling a dehydration condensation reaction between a hydrazide-terminated polyethylene glycol and/or lactose hydrazide and the ketone carbonyl-introduced hydrophobic antitumor drug. The ketone carbonyl-introduced hydrophobic antitumor drug is obtained by reacting an isocyanate group in a compound containing isocyanate group and ketone carbonyl group with a hydroxyl on a hydroxyl-containing hydrophobic antitumor drug. The hydroxyl-containing hydrophobic antitumor drug includes at least one of paclitaxel, docetaxel, paclitaxel derivatives, or docetaxel derivatives.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: December 5, 2023
    Assignee: Jiangsu Jibeier Pharmaceutical Co. Ltd.
    Inventors: Deyue Yan, Zhongyi Geng, Yao Wang, Xinyuan Zhu, Wei Huang, Yongfeng Zhou
  • Patent number: 11833203
    Abstract: There are described novel compounds of formula I: (I) in which, in which A1, A2, A3, A4, R1 and R2 are each as herein defined, for use in the treatment or alleviation of an RAR mediated condition; and methods related thereto.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: December 5, 2023
    Inventors: Andrew Whiting, Carrie Ambler, Mark Coles, David Chisholm